Non-Muscle-invasive Bladder Cancer (NMIBC) Terminated Phase 3 Trials for Docetaxel (DB01248)

Back to Non-Muscle-invasive Bladder Cancer (NMIBC)

Also known as: Non-Muscle- Invasive Bladder Cancer / NMIBC / Non-muscle Invasive Bladder Cancer / Non Muscle-invasive Bladder Cancer / Non-muscle-invasive Bladder Cancer / Non-muscle Invasive Bladder Cancer (NMIBC) / Non Muscle Invasive Bladder Cancer / Nonmuscle Invasive Bladder Cancer / Non-Muscle Invasive Bladder Neoplasms / Carcinoma of urinary bladder, superficial (disorder) / Urothelial carcinoma bladder / Bladder transitional cell carcinoma / Transitional cell carcinoma of bladder (disorder)

Indication	Status	Phase
DBCOND0082324 (Non-Muscle-invasive Bladder Cancer (NMIBC))	Terminated	3

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT02982395	Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC	Treatment	Docetaxel (DB01248) Ethanol (DB00898) Mitomycin (DB00305) Polysorbate 80 (DB11063)